Search Results - "Lamy de la Chapelle, T"

Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study by Bommier, C, Donzel, M, Rossi, C, Fornecker, L M, Bijou, F, Chauchet, A, Lebras, L, Ysabaert, L, Haioun, C, Bouabdallah, K, Gastinne, T, Morineau, N, Amorim, S, Jardin, F, Abraham, J, Lamy de la Chapelle, T, Gressin, R, Fouillet, L, Fruchart, C, Olivier, G, Morschhauser, F, Cherblanc, F, Belot, A, Le Guyader, S, Monnereau, A, Ghesquieres, H, Thieblemont, C

“…Marginal Zone Lymphoma (MZL) comprises three subtypes: extranodal MZL (EMZL), splenic MZL (SMZL) and nodal MZL (NMZL). Since clinical trials have limited…”
Get full text

REMISSION AFTER CAR T‐CELLS: DO PATIENTS RECOVER A NORMAL LIFE? by Alya, P., Colin, F., Charton, E., Anota, A., Guibert, S., Ysebaert, L., Manson, G., Daufresne, P., Lhomme, F., Le Bars, L., Bellec, A., Lamy de la Chapelle, T., Houot, R., Moignet, A.

Get full text

Remote monitoring of CAR T‐cell treated patients by a specialized nurse to detect and manage late complications: report of the CARAMA program by Colin, F., Bellec, A., Le Bars, L., Granger, M., Guibert, S., Manson, G., Lhomme, F., Marchand, T., Mear, J., Barbe, M. Escoffre, Decaux, O., Lamy de la Chapelle, T., Houot, R., Autrel, A. Moignet

Get full text

REALMA: Subset of patients with Marginal Zone Lymphomas from the French nationwide REALYSA real‐world prospective cohort by Bommier, C., Donzel, M., Rossi, C., Fornecker, L., Bijou, F., Chauchet, A., Lebras, L., Ysebaert, L., Haioun, C., Bouabdallah, K., Morineau, N., Gastinne, T., Amorim, S., Jardin, F., Abraham, J., Lamy de la Chapelle, T., Gressin, R., Fouillet, L., Fruchart, C., Morschhauser, F., Olivier, G., Cherblanc, F., Belot, A., Le Guyader, S., Monnereau, A., Ghesquières, H., Thieblemont, C.

Get full text

OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS. RESULTS OF LYMA‐101 TRIAL, A LYSA GROUP STUDY by Le Gouill, S., Beldi‐Ferchiou, A., Cacheux, V., Salles, G., Canioni, D., Bodet‐Milin, C., Alcantara, M., Delwail, V., Gastinne, T., Thieblemont, C., Maisonneuve, H., Lamy de la Chapelle, T., Oberic, l., Bouabdallah, K., Ribrag, V., Delfau‐Larue, M., Macintyre, E., Hermine, O.

Get full text

RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY by Delfau‐Larue, M.H., Boulland, M.L., Feugier, P., Maisonneuve, H., Casasnovas, O., Haioun, C., Pica, G.M., Lamy de la Chapelle, T., Ysebaert, L., Tilly, H., Eisenmann, J.C., Le Gouil, S., Ribrag, V., Jardel, H., Glaisner, S., Cartron, G., Salles, G., Xerri, L., Fest, T., Morschhauser, F.

Get full text

Patients suffering from acute graft-versus-host disease after bone-marrow transplantation have functional CD4+CD25hiFoxp3+ regulatory T cells by Noël, G, Bruniquel, D, Birebent, B, DeGuibert, S, Grosset, J-M, Bernard, M, Dauriac, C, Chevallier, P, Lamy-de-la-Chapelle, T, Semana, G, Brinster, C

“…Acute Graft-Versus-Host Disease (aGVHD), mediated by CD4(+) and CD8(+) effector T cells, is a life-threatening complication in hematopoietic stem cell (HSC)…”
Get full text

RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY by Delfau‐Larue, M.H., Boulland, M.L., Feugier, P., Maisonneuve, H., Casasnovas, O., Haioun, C., Pica, G.M., Lamy de la Chapelle, T., Ysebaert, L., Tilly, H., Eisenmann, J.C., Le Gouil, S., Ribrag, V., Jardel, H., Glaisner, S., Cartron, G., Salles, G., Xerri, L., Fest, T., Morschhauser, F.

Get full text

PS1517 MILD COGNITIVE IMPAIRMENT, HYPOALBUMINEMIA, HIGH CRP AND GASTRO‐INTESTINAL ULCER: 4 MARKERS OF FRAILTY WHICH IDENTIFY OLDER PATIENTS WITH MALIGNANT HEMOPATHIES WHO DON’T BENEFIT FROM CHEMOTHERAPY by Thibaud, V., Deneve, L., Dubruille, S., Kenis, C., Delforge, M., Dal Lago, L., Borghgraef, C., Wildiers, H., Pepersack, T., Chapelle, T. Lamy, Bron, D.

“…Background: Areliable frailty score remains needed to better define the unsuspected vulnerable population that does not benefit from chemotherapy. In the…”
Get full text

Patients suffering from acute graft-versus-host disease after bone-marrow transplantation have functional CD4 +CD25 hiFoxp3 + regulatory T cells by Noël, G., Bruniquel, D., Birebent, B., DeGuibert, S., Grosset, J-M., Bernard, M., Dauriac, C., Chevallier, P., Lamy-de-la-chapelle, T., Semana, G., Brinster, C.

“…Acute Graft-Versus-Host Disease (aGVHD), mediated by CD4 + and CD8 + effector T cells, is a life-threatening complication in hematopoietic stem cell (HSC)…”
Get full text

Regulatory CD4 super(+)CD25 super(h) super(i) T cells conserve their function and phenotype after granulocyte colony-stimulating factor treatment in human hematopoietic stem cell transplantation by Noel, G, Bruniquel, D, DeGuibert, S, Birebent, B, Grosset, J M, Bernard, M, Dauriac, C, Lamy-de-la-Chapelle, T, Semana, G, Brinster, C

“…Acute graft-versus-host disease (aGVHD), mediated by CD4 super(+) and CD8 super(+) effector T cells, is a life-threatening complication in hematopoietic stem…”
Get full text

Patients suffering from acute graft-versus-host disease after bone-marrow transplantation have functional CD4+ CD25hi Foxp3+ regulatory T cells by Noël, G, Bruniquel, D, Birebent, B, DeGuibert, S, Grosset, J-M, Bernard, M, Dauriac, C, Chevallier, P, Lamy-de-la-chapelle, T, Semana, G, Brinster, C

“…Abstract Acute Graft-Versus-Host Disease (aGVHD), mediated by CD4+ and CD8+ effector T cells, is a life-threatening complication in hematopoietic stem cell…”
Get full text

Comparaison IRM de diffusion corps entier et TEP/TDM au 18FDG dans le diagnostic de myélome symptomatique by Brillet, É., Decaux, O., Bernard, A.-M., Devillers, A., Lamy de la Chapelle, T., Bertaud-Gounot, V., Saint-Jalmes, H., Guillin, R., Garin, É., Duvauferrier, R.

“…Notre travail a pour objectif d’évaluer la restriction en IRM de diffusion corps entier (DWMRI) comme marqueur diagnostique du myélome en comparaison à la…”
Get full text